EU Says Teva, Cephalon Deal Violated Antitrust Rules
A 2005 deal between Israeli generic-drug maker Teva and its subsidiary Cephalon to keep a generic version of narcolepsy drug Provigil off the market unlawfully restricted competition in Europe, antitrust watchdogs...To view the full article, register now.
Already a subscriber? Click here to view full article